Kawasaki Disease: epidemiology, pathophysiology, diagnosis, and treatment
DOI:
https://doi.org/10.5281/zenodo.13134370Keywords:
Kawasaki Disease, Rash, VasculitisAbstract
Kawasaki Disease (KD) is a systemic vasculitis that predominantly affects children under five years old, being one of the leading causes of acquired heart disease in childhood in developed countries. It is characterized by prolonged fever, skin rashes, and inflammation of multiple organs. The exact etiology of KD is unknown, but it is believed that genetic and environmental factors play a significant role. Diagnosis is based on specific clinical criteria and can be supported by laboratory and imaging tests. Standard treatment includes the administration of intravenous immunoglobulin (IVIG) and aspirin, with therapeutic alternatives available for refractory cases. The prognosis depends on the promptness of diagnosis and the effectiveness of treatment, with the formation of coronary aneurysms being the main long-term complication.
References
BURNS, J.C.; GLODÉ, M.P. Kawasaki syndrome. Lancet. 2004;364(9433):533-544.
FUKAZAWA, R.; YOSHIMURA, K.; MIKAMI, Y.; et al. Recent advances in the treatment and understanding of Kawasaki disease. Journal of Infection and Chemotherapy. 2021;27(4):542-552.
MCCRINDLE, B.W.; NEWBURGER, J.W.; ROWLEY, A.H.; et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation. 2017;135(17):e927-e999.
NEWBURGER, J.W.; TAKAHASHI, M.; BURNS, J.C. Kawasaki Disease. Journal of the American College of Cardiology. 2016;67(14):1738-1749.
ONOUCHI, Y. The genetics of Kawasaki disease. Current Opinion in Rheumatology. 2018;30(5):651-657.
ROWLEY, A.H. Incomplete (atypical) Kawasaki disease. Pediatric Infectious Disease Journal. 2002;21(6):563-565.
SHULMAN, S.T.; ROWLEY, A.H. Advances in Kawasaki disease. European Journal of Pediatrics. 2004;163(6):285-291.
TREMOULET, A.H.; CHANDRASEKAR, D.; JAIN, S.; et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9930):1731-1738.
YOSHIKAWA, N.; KAWAMOTO, T.; UEDA, K.; et al. Coronary artery abnormalities in Kawasaki disease: from acute phase to long-term follow-up. Pediatric Cardiology. 2020;41(6):1122-1131.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Journal of Social Issues and Health Sciences (JSIHS)
This work is licensed under a Creative Commons Attribution 4.0 International License.
